Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 30, 2019 |
Dec. 31, 2017
USD ($)
|
Dec. 31, 2017
ILS (₪)
|
May 31, 2017
USD ($)
|
Jun. 30, 2015
USD ($)
|
Jun. 30, 2020
USD ($)
shares
|
Jun. 30, 2020
ILS (₪)
shares
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
Dec. 31, 2017
USD ($)
|
Jun. 30, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | $ 726 | |||||||||||
| Percentage of approved budget | 85.00% | 85.00% | 30.00% | 30.00% | ||||||||
| Contingent obligation | $ 643 | $ 585 | $ 903 | $ 889 | ||||||||
| New application of total budget amount | $ 3,100 | |||||||||||
| Other commitments, description | The program is for the period beginning January 2020 through December 2020. | The program is for the period beginning January 2020 through December 2020. | The program is for the period beginning July 2019 through December 2019. | The program is for the period beginning July 2019 through December 2019. | ||||||||
| Additional budget | $ 11,900 | |||||||||||
| Amount of liabilities recorded to agreement | $ 398 | 217 | ||||||||||
| License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | $ 1,800 | |||||||||||
| Annual license fees | $ 10 | |||||||||||
| NIS [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | ₪ | ₪ 2,700 | |||||||||||
| New application of total budget amount | ₪ | ₪ 10,800 | |||||||||||
| Additional budget | ₪ | 41,100 | |||||||||||
| 2017 License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Consideration percentage | 1.00% | |||||||||||
| Annual license fees | $ 10 | 10 | ||||||||||
| Additional Application [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Additional budget | $ 500 | 4,400 | ||||||||||
| Commitments and Contingent Liabilities, description | (i) to pay a license issue fee of $20 thousand and annual license fees ranging from $15 thousand to $25 thousand and (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and (iii) make tiered royalty payments, in the low single digits based on future revenue. | The Company will pay annual license fee of between $15 thousand to $25 thousand subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and royalty payments based on future revenue. | ||||||||||
| Additional Application [Member] | NIS [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Additional budget | ₪ | ₪ 1,600 | ₪ 15,600 | ||||||||||
| 2015 License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Consideration percentage | 1.00% | |||||||||||
| Maximum [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||
| Annual license fees | $ 15 | |||||||||||
| Minimum [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||
| Annual license fees | $ 25 | |||||||||||
| Loan Agreements [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Outstanding balance of the loan | $ 19 | |||||||||||
| Aggregate amount of the remaining potential commitment | $ 89 | 260 | ||||||||||
| Number of common stocks granted | shares | 5,700 | 5,700 | ||||||||||
| Patent License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Other commitments, description | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues. | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues. | ||||||||||
| Annual license fees | $ 25 | |||||||||||
| Maximum payments of license maintenance fees | $ 250 | |||||||||||
| Amount of liabilities recorded to agreement | $ 156 | $ 108 | ||||||||||
| Party to a license agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Other commitments, description | The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $89 thousand and $260 thousand, respectively. | The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $89 thousand and $260 thousand, respectively. | ||||||||||